A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1)

This study is testing a new experimental drug called AZD9574 to see if it can stop cancer cells from repairing themselves. By blocking this repair process, researchers hope to find a more effective way to treat advanced cancers that have not responded to other therapies.

This trial is for people with advanced ovarian, breast, prostate, or pancreatic cancers that have certain genetic mutations, such as BRCA. You must be physically active and stable, with organ function that allows you to safely receive the study treatments.

Participants will receive the experimental drug, sometimes combined with other cancer medications, and will be monitored closely by a medical team. You may also undergo special imaging tests using a tracer to help doctors see how the drug is affecting your tumor.

The study is currently recruiting patients at medical centers in La Jolla, Los Angeles, and San Francisco, California. It is an open-label study, meaning both you and your doctor will know exactly which treatment you are receiving.